Karyopharm Therapeutics Inc. Federal Income Tax Expense (Benefit), Continuing Operations
Karyopharm Therapeutics Inc. (KPTI) reported Federal Income Tax Expense (Benefit), Continuing Operations of -$96.68 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-15.
Discontinued › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2016-03-15
- Karyopharm Therapeutics Inc. federal income tax expense (benefit), continuing operations for fiscal 2015 was -$96.68M.
- Karyopharm Therapeutics Inc. federal income tax expense (benefit), continuing operations for fiscal 2014 was -$72.89M.
- Karyopharm Therapeutics Inc. federal income tax expense (benefit), continuing operations for fiscal 2013 was -$23.02M.
- Karyopharm Therapeutics Inc. federal income tax expense (benefit), continuing operations for fiscal 2012 was -$15.89M.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 12 month | Federal Income Tax Expense (Benefit), Continuing Operations 12 month as first filed |
|---|---|---|
| 2015-12-31 | -$96.68M 10-K · filed 2016-03-15 | |
| 2014-12-31 | -$72.89M 10-K · filed 2016-03-15 | -$73.44M 10-K · filed 2015-03-13 |
| 2013-12-31 | -$23.02M 10-K · filed 2016-03-15 | |
| 2012-12-31 | -$15.89M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |